( Conversely, one commenter requested we indicate in the final rule that the allowed amounts would not represent a guaranteed price because they do not necessarily represent the amount an individual would expect to pay for the item or service
In the CY 2020 OPPS/ASC final rule with comment period, we finalized an alternative pathway for devices that are granted a Breakthrough Device designation (84 FR 61295) and receive FDA marketing authorization for the indication covered by the Breakthrough Device designation
ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver
Available from: LinkOpens in New Tab [Accessed October 23, 2020]
Another official, Russell Wesdyk, encouraged the industry to pursue FDA investigational new drug applications and to conduct trials in humans to evaluate the substances
Read more about these FDA concerns here